Enanta Pharmaceuticals
ENTA
144 hedge funds and large institutions have $539M invested in Enanta Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 63 increasing their positions, 30 reducing their positions, and 20 closing their positions.
110% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 30
70% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 20
10% more funds holding
Funds holding: 131 → 144 (+13)
11% less call options, than puts
Call options by funds: $654K | Put options by funds: $734K
13% less capital invested
Capital invested by funds: $621M → $539M (-$81M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
Top Sellers
ENTA Hedge Fund Activity: Q3 2015 in Review
144 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q3 2015, worth a combined $539M — down 13% from $621M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new ENTA positions and 20 closed out — a net gain of 14 holders — while 63 added to existing stakes and 30 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $21.2M. The largest seller was Consonance Capital Management, cutting an estimated $28.8M.
- 144 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q3 2015, up from 131 in Q2 2015.
- Funds reported $539M of Enanta Pharmaceuticals stock for Q3 2015, down 13% quarter-over-quarter.
- 34 funds opened new Enanta Pharmaceuticals positions in Q3 2015 and 20 closed out, a net change of +14 holders.
- The largest Enanta Pharmaceuticals buyer in Q3 2015 was BlackRock Fund Advisors, an estimated $21.2M added.
- The largest Enanta Pharmaceuticals seller in Q3 2015 was Consonance Capital Management, an estimated $28.8M sold.
Based on aggregated 13F filings for Q3 2015.